China Sentences Canadian to Death for Drugs Amid Strained Ties
(Bloomberg) --
A Chinese court sentenced a Canadian man to death on drug charges, a decision that follows capital punishment rulings handed down to other Canadians and comes as ties between Beijing and Ottawa remain fraught.
The Guangzhou Intermediate People's Court on Thursday sentenced Canadian Xu Weihong to death on charges related to the production of drugs, China's Global Times reported. Xu and alleged accomplice Wen Guanxiong were convicted for producing ketamine, with police confiscating 266 pounds of the drug from Xu's home in Guangzhou and another address, according to the Associated Press, which cited local media reports.
Broader relations between the two countries have been strained since Canadian officials arrested Huawei Technologies Co. Chief Financial Officer Meng Wanzhou in Vancouver in 2018, a move that was immediately followed by Beijing detaining two Canadian citizens working in China, Michael Kovrig and Michael Spavor.
Last year, China sentenced Canadian Robert Lloyd Schellenberg to death on drug trafficking charges, a move that came shortly after Meng's arrest and which Canadian Prime Minister Justin Trudeau denounced as “arbitrary.” Another Canadian national, Fan Wei, was also subsequently given the death penalty by a Chinese court.
Chinese Foreign Ministry spokesman Wang Wenbin said Thursday that the case was handled independently and according to the law, adding that it should not have any impact on Canada-China relations.
“Keeping the death sentence will deter serious criminals,” Wang said. “People are equal in front of the law and criminals of all nationalities in China are treated equally.”
©2020 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.